RE: Another 3 million shares22 Sep 2023 09:05
Mr Jimi,
Reading the document again and the reason why GDR jumped into a 2 year deal with RF is stated. Short term revenue is expected. You can argue what is meant by short term but clearly Mr Budd's resignation suggests this particular KPI was not hit. The extract below reads like a ridiculously optimistic pitch on Dragons Den. To which the dragons would reply "Total available market opportunity is £300 million, what is your revenue at the moment?"
"£0"
"/What is your cash burn per month?"
"£300-400k"
"Thankyou. I'm out" .
" The
Company sees attractive short and long term revenue opportunities for its novel AIHL test for use in
neonatal acute care settings and also for the CYP2C19 test, a point of care product with a number of
performance differentiating features which is in the final stages of development and which the Company
is now planning to launch in the United Kingdom circa September/October 2023.
8
The markets that the Company is targeting are significant relative to its size. The Company estimates
the Total Available Market opportunity of its assays is over £300 million based on end user pricing, and
believes that there are currently no other MT-RNR1 products that can deliver time critical results in under
1 hour. The Genedrive® CYP2C19 assay has limited competition (which currently has a more limited
genetic analysis and usability compared to genedrive's proposed solution)."